Revvity, Inc. logo
Revvity, Inc. (RVTY)
Compare

Revvity, Inc. (RVTY) EV/Sales Ratio: 4.63x

Is Revvity, Inc.’s EV/Sales ratio high or low?

Revvity, Inc.'s EV/Sales ratio of 4.63x is 17% below its 5-year average of 5.57x, near the low end of its 5-year range (3.92x–6.90x).

As of Wednesday, June 17, 2026. 2.88% below its 12-month average of 4.77x.

RVTY EV/Sales Ratio Chart

RVTY EV/Sales Ratio
4.63x-5.12% 1Y
Zoom

RVTY Average EV/Sales Ratio Chart

RVTY Current vs Average EV/Sales Ratio Chart

RVTY EV/Sales Ratio Metrics

EV/SALES RATIO

4.63x

EV/SALES RATIO AVG TTM

4.77x

EV/SALES RATIO AVG 3Y

5.56x

EV/SALES RATIO AVG 5Y

5.57x

EV/SALES RATIO AVG 10Y

4.80x

EV/SALES RATIO AVG 15Y

3.97x

EV/SALES RATIO AVG 20Y

3.39x

CURRENT VS TTM AVG

-2.88%

CURRENT VS 3Y AVG

-16.66%

CURRENT VS 5Y AVG

-16.88%

CURRENT VS 10Y AVG

-3.51%

CURRENT VS 15Y AVG

+16.50%

CURRENT VS 20Y AVG

+36.67%

RVTY Competitors' EV/Sales Ratio

NAMEMARKET CAPEV/SALES RATIOTTM3Y5Y
Revvity, Inc. (RVTY)$10.91B4.63x4.77x5.56x5.57x
Walgreens Boots Alliance, Inc. (WBA)vs ›$10.37B0.25x0.26x0.37x0.45x
Baxter International Inc. (BAX)vs ›$10.19B1.61x1.71x2.16x2.63x
Align Technology, Inc. (ALGN)vs ›$12.43B2.80x2.72x4.05x5.87x
The Cooper Companies, Inc. (COO)vs ›$12.69B3.55x4.14x5.15x5.80x
Solventum Corporation (SOLV)vs ›$12.91B2.13x2.19x2.26x2.26x
Charles River Laboratories International, Inc. (CRL)vs ›$8.78B2.93x2.80x3.02x3.78x
Medpace Holdings, Inc. (MEDP)vs ›$13.05B4.74x6.02x5.55x5.39x
Tempus AI, Inc. (TEM)vs ›$8.51B6.99x11.36x12.16x12.16x
DaVita Inc. (DVA)vs ›$13.46B1.94x1.81x1.84x1.85x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

  • It works for unprofitable companies where P/E doesn't apply
  • Revenue is harder to manipulate than earnings
  • It supports comparisons across companies at different profitability stages
  • It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

Revvity, Inc. EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Revvity, Inc. EV/Sales Ratio FAQ

What is the EV/Sales ratio for Revvity, Inc. (RVTY)?
The EV/Sales ratio for RVTY stock is 4.63x.
Is Revvity, Inc.'s EV/Sales ratio high or low?
Revvity, Inc.'s EV/Sales ratio of 4.63x is 17% below its 5-year average of 5.57x, near the low end of its 5-year range (3.92x–6.90x).
What is the TTM average EV/Sales ratio for Revvity, Inc. (RVTY)?
The TTM average EV/Sales ratio for RVTY stock is 4.77x.
What is the 3Y average EV/Sales ratio for Revvity, Inc. (RVTY)?
The 3Y average EV/Sales ratio for RVTY stock is 5.56x.
What is the 5Y average EV/Sales ratio for Revvity, Inc. (RVTY)?
The 5Y average EV/Sales ratio for RVTY stock is 5.57x.
What is the 10Y average EV/Sales ratio for Revvity, Inc. (RVTY)?
The 10Y average EV/Sales ratio for RVTY stock is 4.80x.
What is the 15Y average EV/Sales ratio for Revvity, Inc. (RVTY)?
The 15Y average EV/Sales ratio for RVTY stock is 3.97x.
What is the 20Y average EV/Sales ratio for Revvity, Inc. (RVTY)?
The 20Y average EV/Sales ratio for RVTY stock is 3.39x.

Revvity, Inc. EV/Sales Ratio History

DATEEV/SALES RATIO
2026-06-174.63x
2026-06-164.76x
2026-06-154.73x
2026-06-124.70x
2026-06-114.77x
2026-06-104.76x
2026-06-094.87x
2026-06-084.72x
2026-06-054.65x
2026-06-044.80x
2026-06-034.75x
2026-06-024.73x
2026-06-014.73x
2026-05-294.89x
2026-05-284.76x
2026-05-274.59x
2026-05-264.59x
2026-05-224.59x
2026-05-214.53x
2026-05-204.51x
2026-05-194.55x
2026-05-184.54x
2026-05-154.48x
2026-05-144.57x
2026-05-134.52x
2026-05-124.69x
2026-05-114.83x
2026-05-084.91x
2026-05-074.83x
2026-05-064.84x
2026-05-054.57x
2026-05-044.34x
2026-05-014.35x
2026-04-304.34x
2026-04-294.17x
2026-04-284.29x
2026-04-274.35x
2026-04-244.35x
2026-04-234.36x
2026-04-224.65x
2026-04-214.65x
2026-04-204.60x
2026-04-174.63x
2026-04-164.46x
2026-04-154.59x
2026-04-144.62x
2026-04-134.58x
2026-04-104.47x
2026-04-094.49x
2026-04-084.49x
2026-04-074.39x
2026-04-064.41x
2026-04-024.43x
2026-04-014.39x
2026-03-314.38x
2026-03-304.27x
2026-03-274.23x
2026-03-264.36x
2026-03-254.39x
2026-03-244.38x
2026-03-234.36x
2026-03-204.32x
2026-03-194.31x
2026-03-184.28x
2026-03-174.37x
2026-03-164.34x
2026-03-134.30x
2026-03-124.27x
2026-03-114.46x
2026-03-104.49x
2026-03-094.56x
2026-03-064.53x
2026-03-054.74x
2026-03-044.81x
2026-03-034.71x
2026-03-024.70x
2026-02-274.81x
2026-02-264.83x
2026-02-254.78x
2026-02-244.78x
2026-02-234.93x
2026-02-205.07x
2026-02-195.05x
2026-02-184.96x
2026-02-174.84x
2026-02-134.89x
2026-02-124.87x
2026-02-115.10x
2026-02-105.25x
2026-02-095.17x
2026-02-065.12x
2026-02-055.03x
2026-02-045.21x
2026-02-035.10x
2026-02-025.35x
2026-01-305.42x
2026-01-295.41x
2026-01-285.52x
2026-01-275.66x
2026-01-265.67x
2026-01-235.75x
2026-01-225.79x
2026-01-215.74x
2026-01-205.55x
2026-01-165.57x
2026-01-155.69x
2026-01-145.53x
2026-01-135.48x
2026-01-125.21x
2026-01-095.24x
2026-01-085.12x
2026-01-075.18x
2026-01-065.26x
2026-01-055.14x
2026-01-024.97x
2025-12-314.92x
2025-12-304.94x
2025-12-294.93x
2025-12-264.92x
2025-12-244.92x
2025-12-234.95x
2025-12-224.96x
2025-12-194.89x
2025-12-184.89x
2025-12-174.92x
2025-12-164.90x
2025-12-155.01x
2025-12-125.07x
2025-12-115.22x
2025-12-105.20x
2025-12-095.00x
2025-12-085.04x
2025-12-055.08x
2025-12-045.16x
2025-12-035.19x
2025-12-025.17x
2025-12-015.15x
2025-11-285.24x
2025-11-265.25x
2025-11-255.28x
2025-11-245.08x
2025-11-214.98x
2025-11-204.80x
2025-11-194.73x
2025-11-184.76x
2025-11-174.68x
2025-11-144.75x
2025-11-134.78x
2025-11-124.81x
2025-11-114.81x
2025-11-104.73x
2025-11-074.67x
2025-11-064.61x
2025-11-054.74x
2025-11-044.70x
2025-11-034.76x
2025-10-314.78x
2025-10-304.67x
2025-10-294.85x
2025-10-284.90x
2025-10-274.93x
2025-10-245.01x
2025-10-234.95x
2025-10-224.87x
2025-10-214.92x
2025-10-204.85x
2025-10-174.78x
2025-10-164.80x
2025-10-154.72x
2025-10-144.68x
2025-10-134.67x
2025-10-104.56x
2025-10-094.70x
2025-10-084.71x
2025-10-074.68x
2025-10-064.77x
2025-10-034.80x
2025-10-024.69x
2025-10-014.71x
2025-09-304.53x
2025-09-294.39x
2025-09-264.38x
2025-09-254.34x
2025-09-244.40x
2025-09-234.45x
2025-09-224.47x
2025-09-194.49x
2025-09-184.54x
2025-09-174.44x
2025-09-164.43x
2025-09-154.38x
2025-09-124.33x
2025-09-114.45x
2025-09-104.32x
2025-09-094.42x
2025-09-084.48x
2025-09-054.49x
2025-09-044.45x
2025-09-034.35x
2025-09-024.54x
2025-08-294.64x
2025-08-284.60x
2025-08-274.57x
2025-08-264.68x
2025-08-254.72x
2025-08-224.81x
2025-08-214.62x
2025-08-204.70x
2025-08-194.69x
2025-08-184.62x
2025-08-154.66x
2025-08-144.61x
2025-08-134.67x
2025-08-124.55x
2025-08-114.46x
2025-08-084.50x
2025-08-074.48x
2025-08-064.46x
2025-08-054.58x
2025-08-044.62x
2025-08-014.62x
2025-07-314.61x
2025-07-304.73x
2025-07-294.89x
2025-07-284.92x
2025-07-255.29x
2025-07-245.22x
2025-07-235.11x
2025-07-224.96x
2025-07-214.73x
2025-07-184.84x
2025-07-174.94x
2025-07-164.91x
2025-07-154.95x
2025-07-145.06x
2025-07-115.20x
2025-07-105.23x
2025-07-095.14x
2025-07-085.16x
2025-07-075.07x
2025-07-035.19x
2025-07-025.17x
2025-07-015.09x
2025-06-304.99x
2025-06-275.04x
2025-06-265.08x
2025-06-255.03x
2025-06-244.97x
2025-06-234.91x
2025-06-204.91x
2025-06-184.89x
2025-06-174.88x
2025-06-164.97x
2025-06-134.85x
2025-06-124.94x
2025-06-114.96x
2025-06-104.97x
2025-06-094.82x
2025-06-064.78x
2025-06-054.72x

Showing the most recent 260 of 4,969 data points. The chart above shows the full history.

About Revvity, Inc.

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.

Waltham, MA
11,000 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Prahlad R. Singh